Patents by Inventor Barbara Belisle

Barbara Belisle has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20120208197
    Abstract: The cell-based assays described in the present invention can be used to directly assess the sensitivity and specificity of the gene annotation reagent against its target, mapping genes and to determine if a non-targeted gene participates in a pathway of interest or is functionally linked to another gene or protein. Preferred assay embodiments include fluorescence or luminescence assays in intact (live or fixed) cells. Such fluorescence or luminescence assays include high-throughput or high-content assays for protein activity, subcellular localization, post-translational modifications, or interactions of proteins. Suitable assays may include protein-protein interaction assays; protein translocation assays; and post-translational modification assays. The invention can be used to assess the efficacy of any gene silencing experiment, and to map novel genes into biochemical pathways, and to identify novel pharmaceutical targets.
    Type: Application
    Filed: August 29, 2011
    Publication date: August 16, 2012
    Applicant: Odyssey Thera, Inc.
    Inventors: Stephen William Watson Michnick, Barbara Belisle, Marnie L. MacDonald, John K. Westwick, Jane Elizabeth Lamerdin
  • Publication number: 20080064040
    Abstract: The cell-based assays described in the present invention can be used to directly assess the sensitivity and specificity of the gene annotation reagent against its target, and to determine if a non-targeted gene participates in a pathway of interest or is functionally linked to another gene or protein. The combination of annotation reagents with such cell-based assays is useful for mapping genes (proteins) into cellular pathways on a genome-wide scale. Preferred assay embodiments include fluorescence or luminescence assays in intact (live or fixed) cells. Such fluorescence or luminescence assays include high-throughput or high-content assays for protein activity, subcellular localization, post-translational modifications, or interactions of proteins. Suitable assays may include protein-protein interaction assays; protein translocation assays; and post-translational modification assays.
    Type: Application
    Filed: June 29, 2007
    Publication date: March 13, 2008
    Applicant: Odyssey Thera, Inc.
    Inventors: Stephen Watson Michnick, Barbara Belisle, Marnie MacDonald, John Westwick, Jane Lamerdin
  • Publication number: 20040241636
    Abstract: The cell-based assays described in the present invention can be used to directly assess the sensitivity and specificity of the gene annotation reagent against its target, and to determine if a non-targeted gene participates in a pathway of interest or is functionally linked to another gene or protein. The combination of annotation reagents with such cell-based assays is useful for mapping genes (proteins) into cellular pathways on a genome-wide scale. Preferred assay embodiments include fluorescence or luminescence assays in intact (live or fixed) cells. Such fluorescence or luminescence assays include high-throughput or high-content assays for protein activity, subcellular localization, post-translational modifications, or interactions of proteins. Suitable assays may include protein-protein interaction assays; protein translocation assays; and post-translational modification assays.
    Type: Application
    Filed: May 29, 2004
    Publication date: December 2, 2004
    Inventors: Stephen William Watson Michnick, Barbara Belisle, Marnie L. MacDonald, John K. Westwick, Jane Elizabeth Lamerdin